RAV 12

Drug Profile

RAV 12

Alternative Names: ANTI-RAAG12-MAB; RAV12

Latest Information Update: 14 May 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Raven biotechnologies
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell membrane modulators; Complement activation stimulants; Immunostimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adenocarcinoma; Pancreatic cancer

Most Recent Events

  • 01 May 2012 Discontinued - Phase-I/II for Adenocarcinoma in USA (IV)
  • 01 May 2012 Discontinued - Phase-II for Pancreatic cancer in USA (IV)
  • 17 Jul 2008 Raven biotechnologies has been acquired by MacroGenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top